Released Nov 13, 2024, after the close
10-Q filed Nov 13, 2024, 44 days after period end · 0001390478-24-000021
Q3 2024 · 10-Q
Revenue—
Net Income-$7.11M-$7.11M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.10-$0.10 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$7,329,000N/M
Operating Cash Flowderived-$7,806,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.11M | -$9.27M | -$7.02M | -$7.09M |
| EPS Diluted | -$0.10 | -$0.33 | -$0.34 | -$0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR